TKI-induced DNA methylation changes have been reported in advanced EGFR-mutated lung cancer.33 Decitabine, the DNA methyl transferase inhibitor, could reverse the sensitivity of EGFR-TKI–resistant NSCLC cell line PC9/GR through demethylation of RASSF1A and GADD45β. 34 The combination of TKIs with epigenetic drugs has shown promise as a treatment in preclinical and clinical studies.33-35. The gene discussed is RASSF1; the disease is lung carcinoma.